Article Text

other Versions

PDF
Selective fluconazole prophylaxis in high risk babies to reduce invasive fungal infection
  1. Brian A McCrossan (brianmccrossan{at}doctors.org.uk)
  1. Royal Maternity Hospital, Belfast, United Kingdom
    1. Elaine McHenry (elaine.mchenry{at}bll.n-i.nhs.uk)
    1. Royal Victoria Hospital, Belfast, United Kingdom
      1. Fiona O'Neil (fiona.oneill{at}royalhospitals.n-i.nhs.uk)
      1. Royal Victoria Hospital, Belfast, United Kingdom
        1. Grace Ong (grace.ong{at}bll.n-i.nhs.uk)
        1. Royal Victoria Hospital, Belfast, United Kingdom
          1. David G Sweet (david.sweet{at}royalhospitals.n-i.nhs.uk)
          1. Royal Maternity Hospital, Belfast, United Kingdom

            Abstract

            Objectives:Evaluate impact of selective fluconazole prophylaxis on incidence of invasive fungal infection and emergence of fluconazole resistance in Neonatal Intensive Care (NICU).

            Design:Retrospective study of babies < 1500g birth weight (VLBW) admitted to NICU in a period 1 year before and after implementation of an antifungal prophylaxis guideline.

            Patients:Eligibility: VLBW babies with an additional risk factor: (1) Colonization of candida species from surface sites with a central venous catheter, (2) 3rd generation Cephalosporin treatment or (3) total duration of antibiotic therapy >10 days.

            Fluconazole Protocol:Fluconazole 6mg/kg for 3 weeks. Dose interval every 72 hours during the first 2 weeks of life. Thereafter, dose interval reduced to 48 hourly until 3 weeks old when daily fluconazole is given. Fluconazole administered orally when enteral feeding achieved.

            Results:One hundred and twenty-one and 107 VLBW babies admitted in year before and after guideline, data available in 110 and 102 charts respectively. Thirty-three (33/110) and 31 (31/102) babies were eligible for fluconazole prophylaxis in pre and post prophylaxis periods respectively. Six (6/33) babies eligible for prophylaxis developed culture proven candida sepsis before the guideline compared with no (0/31) babies after (p= 0.03). One baby (1/31) did develop probable candida sepsis in the post prophylaxis period. During both study periods all candida isolates remained fully susceptible to fluconazole.

            Conclusions:Selective anti-fungal prophylaxis has reduced invasive fungal sepsis in our unit without evidence of fluconazole resistance emerging. Abstract word count =235

            • VLBW babies
            • fluconazole
            • fungal sepsis
            • prophylaxis

            Statistics from Altmetric.com

            Request permissions

            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

            Linked Articles

            • Fantoms
              Martin Ward Platt